CEGEDIM-RELATIONSHIP
Cegedim Relationship Management has released its thought leadership white paper, Digital Channel Engagement: A Measurable Opportunity , the third in a series of Cegedim reports on multichannel engagement.
New Trends and Opportunities in Digital Channel Engagement
The
white paper reveals that digital channel engagement offers quantifiable
opportunities for life sciences companies. The report presents the
results of worldwide studies conducted by Cegedim
Strategic Data
(CSD), including Health Care Professionals’ (HCP)
evaluations of various digital channels, as well as an analysis of the
behavioral impact of their interactions with life sciences companies per
channel type. The data provides evidence that in many global markets,
digital engagements increases prescription writing intent.
Within the context of multichannel engagement, digital channels - while still in the early stages of being included in the marketing mix - are increasing in adoption around the world because they:
- Generally require less time of the HCP
- Offer higher flexibility for HCPs to choose the content, time and format they prefer for receiving medical and product insights
- Are more cost effective for life sciences companies
- Tend to be very engaging
“Information now means more to both patients and HCPs. Therefore, life sciences companies must become best-in-class digital content marketers,” said Emiliano Gummati, Vice President of Product Portfolio Management, Cegedim Relationship Management. “To achieve this end, the digital strategy requires an engagement system to collect and analyze interaction data to better comprehend the customer journey throughout each digital channel. The more understanding companies have regarding their customers’ digital presence, the more personalized and effective their communication strategies can become.”
Global Adoption Trends and Prescribing Behavior
Adoption of
digital channel engagement varies in different markets around the world,
according to CSD, with the highest rates being in Japan (34%), the US
(24%) and Poland (20%). Recent research has uncovered strong
opportunities in many markets, including those with lower adoption
rates. For example, in Italy, where only 2% report use of digital
channels - of that group - 43% report that digital engagement positively
impacts their prescription intention.
Cegedim Relationship Management, the global leader in Customer Relationship Management, Healthcare Data, Regulatory Compliance, and Marketing Solutions for the life sciences industry, released this thought leadership white paper in the first quarter of 2015. Please click here to access the report, as well as the first and second reports in the series, 2014 Multichannel: Remote Interactions and 2013 Multichannel: Measuring Effectiveness.
| About Cegedim Relationship Management: |
Cegedim Relationship Management is the Life Sciences industry’s
leading provider of Customer Relationship Management (CRM)
solutions. Designed specifically for Life Sciences, the company’s
innovative business solutions incorporate a thorough understanding
of local, regional and worldwide trends. Cegedim Relationship
Management enables approximately 200,000 users in many of the
world’s most innovative companies to stay ahead of market
challenges. In addition to CRM, Cegedim Relationship Management
also provides marketing, data optimization and regulatory
compliance solutions in more than 80 countries. Cegedim
Relationship Management is part of the France-based Cegedim S.A.
Group.
To learn more, please visit: www.cegedim.com/rm
.
|
||
| About Cegedim: |
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs almost 8,000 people in more than 80 countries and generated revenue of €912 million in 2014. Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit: www.cegedim.com
. |
||
Contact:
Drew BUSTOS
Cegedim Relationship Management
Global
Communications
Tel.: +1 (908) 443.2451
drew.bustos@cegedim.com
or
Aude
BALLEYDIER
Cegedim
Media Relations
Tel.: +33 (0)1 49
09 68 81
aude.balleydier@cegedim.fr
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum